<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755154</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-65487-002</org_study_id>
    <secondary_id>2018-004170-97</secondary_id>
    <nct_id>NCT03755154</nct_id>
  </id_info>
  <brief_title>Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma or Multiple Myeloma</brief_title>
  <official_title>Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic
      (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/
      Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously
      (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML),
      Non-Hodgkin Lymphoma (NHL) or Multiple Myeloma (MM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed in two parts: one part for dose escalation, one part for dose
      expansion.The dose escalation part will be followed by expansion part at the MTD(s)/RP2D(s)

      This study will utilize an adaptative Bayesian Logistic Regression model to guide dose
      escalation and estimate the MTD(s) based on the Dose Limiting Toxicity (DLT) relationship(s)
      for S65487 in the indications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity (DLT)</measure>
    <time_frame>until the end of the first cycle (each cycle is 21days)</time_frame>
    <description>Safety criterion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
    <description>Safety and tolerability criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Serious Adverse Events</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
    <description>Safety and tolerability criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose reductions</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose interruptions</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic (PK) profile of S65487: Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S65487: Volume of distribution at steady-state (Vss)</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S65487: total CLearance (CL)</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S65487: terminal half-life (t½z)</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Best Response observed during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Proportion of patients in whom a complete response (CR) or a partial response (PR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapse or Refractory Acute Myeloid Leukemia</condition>
  <condition>Relapse or Refractory Non-Hodgkin Lymphoma</condition>
  <condition>Relapse or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>S65487</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S65487</intervention_name>
    <description>S65487 is administered as single agent via i.v. infusion on a 3-week cycle.</description>
    <arm_group_label>S65487</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cytologically confirmed and documented de novo, secondary or
             therapy-related AML, excluding acute promyelocytic leukaemia with relapsed or
             refractory disease without established alternative therapy. Or patients with
             measurable confirmed Multiple Myeloma (IMWG) with relapsed or refractory disease who
             have previously received at least three lines of treatment and without established
             alternative therapy. Or patients with histologically and measurable confirmed Non
             Hodgkin Lymphoma defined as Diffuse Large B cell Lymphoma (DLBCL), Follicular Lymphoma
             (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), High-Grade B cell
             Lymphoma with relapsed or refractory disease who have received at least two lines of
             therapy (including rituximab) and without established alternative therapy.

          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.

          -  For NHL and MM patients: haematological function (independent of any growth factor
             support) based on the last assessment performed before inclusion, defined as: absolute
             neutrophil count (ANC) ≥ 1 x 109/L, haemoglobin ≥ 8 g/dL, platelet count ≥ 50 x 109/L.

          -  For AML patients: circulating Blood White Cell count (WBC count) &lt; 25 x 109/L (with or
             without use of hydroxycarbamide) based on the last assessment performed before
             inclusion.

          -  Adequate renal function based on the last assessment performed before inclusion,
             assessed as Glomerular Filtration Rate (GFR) using Modification of Diet in Renal
             Disease (MDRD) Formula.

          -  Adequate hepatic function based on the last assessment performed before inclusion.

        Exclusion Criteria:

          -  Pregnancy, breastfeeding or possibility of becoming pregnant during the study.

          -  Participation in another interventional study at the same time or another
             interventional study requiring investigational treatment intake within 3 weeks or at
             least 5 half-lives (whichever is longer) prior to the first S65487 administration.

          -  Participant already enrolled in the study (informed consent signed) and has received
             at least one dose of S65487.

          -  Patients who have not recovered from toxicity of previous anticancer therapy,
             including grade ≥ 2 non-hematologic toxicity, prior to the first IMP administration
             (including peripheral neurotoxicity). Certain toxicities will not be considered in
             this category (e.g. alopecia).

          -  Patients refractory to a previous treatment with a Bcl-2 inhibitor.

          -  For AML patients : Allogenic stem cell transplant within 3 months before the first IMP
             administration and/or patients who still receive immunosuppressive treatment within 3
             months before the first IMP administration and/or patients with active
             Graft-versus-host disease within 3 months before the first IMP administration and/or
             patient who receive donor lymphocyte infusion (DLI) within 3 months before the first
             IMP administration.

          -  For NHL and MM patients Prior allogenic stem cell transplant before the first IMP
             administration and/or Autologous stem cell transplant within 3 months before the first
             IMP administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad Navarra- Servicio de Hematología</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca- Servicio de Hematología (4a planta)</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe - Servicio de Hematología - Torre F - Planta 7</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Hospital</name>
      <address>
        <city>Bebington</city>
        <zip>L63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SSE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Dose-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
They can ask for all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

